Clinical trial · Observational
Cytological Examination of Malignant Pleural Effusion in Breast Cancer
Diagnostic Yield of Cytological Examination of Malignant Pleural Effusion in Different Breast Cancer Pathologies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Malignant pleural effusion (MPE) is characterized by the presence of malignant cells. It can occur in 15% of patients with cancer and is a common manifestation in patients with metastatic disease. Breast cancer (BC) is the second most common cause of MPE and MPE occurring in 2- 11% of patients with BC. Breast cancer is a heterogeneous disease of malignant tumors with diversified morphology, clinical course, biologic behavior and prognosis, and accurate tumor classification is critical for a patient's care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thoracentesis | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer breast
- description
- malignant pleural effusion in breast cancer
- interventionNames
- Diagnostic Test: Thoracentesis
Primary outcomes (1)
- measure
- Cytological examination of pleural effusion in breast cancer ( cell/unit)
- timeFrame
- 6 months
- description
- Diagnosis of pleural effusion by cytological examination
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients will be included if they are presented for thoracentesis with routine cytological examination of pleural effusion before biopsy or thoracoscopy, if the appearance of visceral and parietal pleural was clearly and if malignant diagnosis of breast was confirmed on histological analysis of the biopsy material. Exclusion Criteria: * Age \<18 years. * Patients diagnosed with malignant pleural mesothelioma (MPM) * Contraindication for pleurocentesis; patient refusing, coagulopathy and active skin infection
References
Publications (0)
Data not yet available